GENE ONLINE|News &
ADC
HanchorBio and InxMed Explore “Barrier Disruption + Myeloid Activation” Strategy for Difficult-to-Treat Solid Tumors
2026-07-08
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
2026-06-29
The Next Decade in Cancer Therapeutics: How Immunotherapy is Evolving from Efficacy to Precision
2026-05-05
Innovative Antibody-Drug Conjugates Show Efficacy Across Advanced Solid Tumors at AACR 2026
2026-04-23
[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
2026-02-05
DISCO Pharmaceuticals and Amgen Ink Exclusive License Deal to Advance Surfaceome-Targeted Cancer Therapies
2026-01-07
A New Order in APAC Biosimilar Market: From Manufacturing Powerhouses to Value-Driven Innovators
2025-11-13
The Biologics Landscape Is Changing—Fast: CDMOs Race to Integrate Development, Scale, and Next-Gen Modalities
2025-10-20
Strategic Outsourcing: How CDMO Partnerships Are Tipping the Scales from Cost Efficiency to Supply Chain Resilience
2025-10-20
LATEST
Definium’s Psychedelic Anxiety Drug DT120 Moves Closer to the Mainstream With a Phase 3 Win
2026-08-14
JAMA Network Open Study Links Agent Orange and Burn Pit Exposure to Veteran Health Outcomes
2026-08-14
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
